Preliminary results of the Spanish Association of Urology National Registry in Active Surveillance for prostate cancer


Por: Rubio-Briones J., Borque A., Esteban L.M., Iborra I., López P.A., Gil J.M., Pallás Y., Fumadó L., Martínez-Breijo S., Chantada V., Gómez E., Quicios C., Congregado C.B., Medina R., Ortiz M., Montesino M., Clar F., Soto J. and Campá J.M.

Publicada: 1 ene 2016
Categoría: Urology

Resumen:
Objectives: To present a National Registry of patients with prostate cancer as monitored through active surveillance, with the intention of testing the hypothesis that cancer-specific mortality in very low-risk and low-risk patients is less than 5% at 15 years. Material and methods: A multicentre observational study (AEU-PIEM/2014/0001) sponsored by the Spanish Association of Urology was conducted using their platform for multicentre studies. The clinical-pathological inclusion criteria were as follows: cT1a-cT3a, PSA <= 20 ng/ml, initial minimum biopsy of 10 cores, number of affected cores <= 3, 1st Gleason score of 3 and 2nd Gleason score <= 4 and a known prostate volume (in cc). A unified follow-up was not established for all recruiting centres; however, a survey was conducted that reflects the follow-up characteristics based on a number of tangible parameters that allow for their comparison. With the same philosophy of flexibility, the use of certain biomarkers and multiparametric MRI was not considered necessary for inclusion. Results: We describe the Registry's characteristics and possibilities, as well as the preliminary results from the 324 patients included in its first 5 months of operation in the 15 recruiting centres. We also report the clinical-pathological variables, biomarkers, radiodiagnosis technique and quality-of-life questionnaires considered for the database, as well as the possibilities for indefinite follow-up, remaining open to any active treatment recognized in clinical guidelines. Conclusions: The AEU-PIEM/2014/0001 represents an extremely useful tool for all Spanish urologists for multicentre clinical research. The registry will undoubtedly enable the dissemination of active surveillance of our patients in a more coordinated manner, thus maintaining the advantages of optimised opportunistic screening for prostate cancer without resulting in overtreatment. (C) 2015 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.

Filiaciones:
Rubio-Briones J.:
 Instituto Valenciano de Oncología, Valencia, Spain

Borque A.:
 Hospital Universitario Miguel Servet, Zaragoza, Spain

Esteban L.M.:
 Escuela Universitaria la Almunia, Zaragoza, Spain

Iborra I.:
 Instituto Valenciano de Oncología, Valencia, Spain

López P.A.:
 Hospital Virgen de la Arrixaca, Murcia, Spain

Gil J.M.:
 Hospital Universitario Miguel Servet, Zaragoza, Spain

Pallás Y.:
 Hospital de Manises, Valencia, Spain

Fumadó L.:
 Hospital del Mar, Barcelona, Spain

Martínez-Breijo S.:
 Hospital Juan Canalejo, La Coruña, Spain

Chantada V.:
 Hospital Juan Canalejo, La Coruña, Spain

Gómez E.:
 Hospital Universitario Reina Sofía, Córdoba, Spain

Quicios C.:
 Fundación Jiménez-Díaz, Madrid, Spain

Congregado C.B.:
 Hospital Universitario Virgen del Rocío, Sevilla, Spain

Medina R.:
 Hospital Universitario Virgen del Rocío, Sevilla, Spain

Ortiz M.:
 Hospital General Universitario de Elche, Alicante, Spain

Montesino M.:
 Complejo Hospitalario de Navarra, Pamplona, Spain

:
 Hospital de la Ribera, Alzira, Valencia, Spain

Soto J.:
 Hospital Universitario Puerta del Mar, Cádiz, Spain

Campá J.M.:
 Hospital Universitario Araba, Álava, Spain
ISSN: 02104806





ACTAS UROLOGICAS ESPANOLAS
Editorial
ENE EDICIONES SL, REDACCION, ADMINISTRACION & PUBLICIDAD, ORURO 9 - BAJO IZDA, MADRID, 28016, SPAIN, Reino Unido
Tipo de documento: Article
Volumen: 40 Número: 1
Páginas: 3-10
WOS Id: 000372298300002
ID de PubMed: 26115777

MÉTRICAS